Literature DB >> 16920201

Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays.

Sherwin Lee1, Owen Wood, Rolf E Taffs, Jinjie Hu, Ana Machuca, Alejandro Vallejo, Indira Hewlett.   

Abstract

Multiple nucleic acid-based techniques (NAT) have been implemented for testing blood and plasma donors for HIV-1 RNA which may be detected at an earlier stage of infection when HIV antigen or antibody is absent or below the limit of detection of current assays. The available NAT assays are based on different technologies. In order to evaluate the performance of nucleic acid-based techniques (NAT assays) and to allow accurate comparisons of results from different assays, it is essential to have well characterized specimens with known copy numbers as a standard. For this purpose, a comprehensive study was conducted to develop two HIV-1 RNA reference panels. The first (Panel 1) was prepared using a single specimen from the HIV-1 group M subtype B and consists of panel members with a wide range of HIV-1 RNA copy numbers. Panel 2 consists of 26 members representing HIV-1 group M subtypes A, C, D, E, F, G and groups O and N. For accurate determination of HIV-1 RNA copy numbers of each member of Panel 2, they were analyzed using various testing platforms/technologies available through the cooperation of five independent laboratories participating in the study. A consensus value for HIV RNA copy number was assigned to each member of Panel 2 based on statistical analysis of the data provided by the participants. Both panels could serve as reference panels to be used by manufacturers of HIV NAT tests to evaluate the sensitivity limits of their assays.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920201     DOI: 10.1016/j.jviromet.2006.07.001

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  4 in total

1.  Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection.

Authors:  Shixing Tang; Jiangqin Zhao; Aifeng Wang; Ragupathy Viswanath; Harri Harma; Richard F Little; Robert Yarchoan; Susan L Stramer; Phillipe N Nyambi; Sherwin Lee; Owen Wood; Eric Y Wong; Xue Wang; Indira K Hewlett
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.

Authors:  Deirdre Church; Daniel Gregson; Tracie Lloyd; Marina Klein; Brenda Beckthold; Kevin Laupland; M John Gill
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

3.  Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.

Authors:  Linda G Apuzzo; Florin Vaida; Joel E Gallant; Karin B Ernstrom; Susan J Little; Jean-Pierre Routy; Ann C Collier; Brian Conway; Martin H Markowitz; Frederick M Hecht; Bruce D Walker; Elizabeth Connick; Joseph B Margolick
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

4.  Development of real-time PCR array for simultaneous detection of eight human blood-borne viral pathogens.

Authors:  Natalia Pripuzova; Richard Wang; Shien Tsai; Bingjie Li; Guo-Chiuan Hung; Roger G Ptak; Shyh-Ching Lo
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.